The ubiquitin E3 ligase Cbl has been shown to negatively regulate tyrosine kinase receptors, including the stem cell factor receptor/c-Kit. Impaired recruitment of Cbl to c-Kit results in a deregulated positive signalling that eventually can contribute to carcinogenesis. Here, we present results showing that Cbl is activated by the SFKs (Src family kinases) and recruited to c-Kit in order to trigger receptor ubiquitination. We demonstrate that phosphorylated Tyr568 and Tyr936 in c-Kit are involved in direct binding and activation of Cbl and that binding of the TKB domain (tyrosine kinase binding domain) of Cbl to c-Kit is specified by the presence of an isoleucine or leucine residue in position +3 to the phosphorylated tyrosine residue on c-Kit. Apart from the direct association between Cbl and c-Kit, we show that phosphorylation of Cbl by SFK members is required for activation of Cbl to occur. Moreover, we demonstrate that Cbl mediates monoubiquitination of c-Kit and that the receptor is subsequently targeted for lysosomal degradation. Taken together, our findings reveal novel insights into the mechanisms by which Cbl negatively regulates c-Kit-mediated signalling.
c-Kit belongs to the family of type III RTKs (receptor tyrosine kinases) and plays a major role in survival, expansion and differentiation of haematopoietic progenitor cells, as well as stem cells involved in reproduction and pigmentation (for a review, see ). Moreover, it is essential for the function of mast cells. These c-Kit-dependent processes are triggered by the binding of SCF (stem cell factor) to c-Kit, which results in dimerization of the receptor and subsequent activation of its intrinsic tyrosine kinase activity. This leads to autophosphorylation of the receptors on specific tyrosine residues, which then serve as docking sites for signalling molecules containing either an SH2 (Src homology 2) domain or a PTB (phosphotyrosine-binding) domain respectively (for a review, see ). Proteins reported to interact with ligand-stimulated c-Kit include PI3K (phosphoinositide 3-kinase), PLC-γ1 (phospholipase C-γ1), STAT (signal transducer and activator of transcription), SFKs (Src family kinases) and a number of adaptor proteins such as Grb2 (growth-factor-receptor-bound protein 2), Grb7, Grb10, Crk and APS (adapter protein with a pleckstrin homology and Src homology domain). Their activation and recruitment normally constitute the first steps in the signal relay cascade from activated c-Kit to intracellular downstream targets.
Under normal circumstances, the activation of c-Kit is tightly regulated and its inappropriate activation is associated with development of a number of malignancies, including acute myeloid leukaemia, small cell lung cancer, gastrointestinal stromal tumours and testicular cancer (for a review, see ). Negative regulation of RTKs occurs through the action of protein tyrosine phosphatases as well as through proteolytic degradation.
Recent studies have shown that a number of RTKs undergo ubiquitination, targeting them for degradation. Ubiquitination serves as a general key regulatory mechanism of signalling in normal cells and is mediated by ubiquitin ligases that attach single or multiple ubiquitin moieties to their targets, resulting in mono- or poly-ubiquitinated proteins respectively. Members of the Cbl family of ubiquitin ligases, namely Cbl, Cbl-b and Cbl-c, play a major role in the ligand-dependent ubiquitination of many RTKs . They all possess a highly conserved N-terminal domain consisting of a TKB domain (tyrosine kinase binding domain) and a RING (really interesting new gene) finger domain, which are both necessary for ubiquitin ligase activity. The TKB domain is required for Cbl recruitment to tyrosine-phosphorylated proteins . The RING finger domain associates with the E2 ubiquitin-conjugating enzyme, UbcH7 (ubiquitin-conjugating enzyme H7) , leading to the transfer of ubiquitin molecules to lysine residues on the target protein. The C-terminal half of Cbl contains a proline-rich region and potential phosphorylation sites, which in turn can allow interaction of Cbl with proteins possessing SH3 or SH2 domains respectively and confer adaptor functions to Cbl proteins (reviewed in ).
Examples of RTKs known to be targeted and negatively regulated by Cbl family members include the receptors for EGF (epidermal growth factor), CSF-1 (colony-stimulating factor-1), PDGF (platelet-derived growth factor), VEGF (vascular endothelial growth factor) and hepatocyte growth factor (c-Met) [8–12]. Upon mono- or poly-ubiquitination, the proteins are destined for degradation via the lysosome or the proteasomes respectively , although in some cases receptors are recycled to the plasma membrane. Dysfunction or impaired recruitment of Cbl to RTKs results in deregulated positive signalling that eventually can lead and contribute to carcinogenesis .
Several reports claim that internalization and degradation of c-Kit are mediated by Cbl in an Src-dependent manner. The current opinion suggests that upon SCF stimulation, SFKs are recruited to autophosphorylated Tyr568 of c-Kit and thereby activated. Active Src kinases then phosphorylate Cbl, which in turn tags the receptor for proteasomal degradation . The interaction of Cbl and c-Kit during these processes has been studied by some groups and so far it is assumed to be primarily mediated indirectly by the adaptor proteins APS or Grb2 [16–18].
In this paper, we present results suggesting that Cbl needs not only to be activated by Src but also to be recruited to c-Kit upon SCF stimulation in order to elicit receptor ubiquitination. We show that the N-terminal TKB domain of Cbl can directly interact with c-Kit at phosphorylated Tyr568 and Tyr936. The binding specificity of Cbl for these tyrosine residues is determined by Ile571 and Leu939 of c-Kit respectively. The specific Cbl loss-of-binding mutant of c-Kit, namely c-Kit I571A/L939A, accordingly failed to bind Cbl, while phosphorylation of Cbl appeared to be intact. Consequently, ubiquitination and degradation of I571A/L939A-c-Kit was retarded despite intact ligand-stimulated kinase activities of c-Kit and Src. Wild-type c-Kit was further found to be primarily monoubiquitinated and targeted to the lysosome for degradation. Thus the present paper adds a novel perspective on the dynamics and regulation of c-Kit signalling with a sequential recruitment of signal transduction molecules such as Src and Cbl to Tyr568 of c-Kit.
Antibodies, ligands and inhibitors
Human recombinant SCF and murine recombinant IL-3 (interleukin-3) were obtained from ProSpec-Tany Technogene (Rehovot, Israel). The rabbit antiserum Kit-C1, recognizing the C-terminal domain of c-Kit, was affinity-purified as described in . The anti-phosphotyrosine antibody 4G10 was from Upstate Biotechnology (Charlottesville, VA, U.S.A.), and anti-GST (glutathione S-transferase) and anti-Cbl (c-15) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). The 9E10 antibody recognizing Myc tag was from Roche Diagnostics, anti-ubiquitin P4D1 from Covance Research Products (Denver, PA, U.S.A.) and anti-ubiquitin FK1 from Biomol (Plymouth Meeting, PA, U.S.A.). The Src antibody Ab-1 was from Oncogene Sciences. Redivue [γ-32P]ATP was purchased from Amersham Biosciences. The Src inhibitor SU6656 was from SUGEN/Calbiochem (San Diego, CA, U.S.A.). PE (phycoerythrin)-conjugated monoclonal YB5.B8 against human c-Kit was from BD Pharmingen. Clasto-lactacystin (Biomol) or chloroquine (Sigma, St. Louis, MI, U.S.A.) was used for proteasomal or lysosomal inhibition respectively. GST fusion proteins of N- and C-terminal parts of Cbl have previously been described .
PAE (porcine aortic endothelial) cells were grown in Ham's F-12 medium with 10% (v/v) FBS (foetal bovine serum), 100 units/ml penicillin and 100 μg/ml streptomycin. COS-1 cells were grown in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10% FBS, 100 units/ml penicillin and 100 μg/ml streptomycin. Cells were cultured in a humidified incubator at 37 °C with 5% CO2. Cells were starved in 0.1% FBS overnight and stimulated with 100 ng/ml SCF for the indicated periods of time unless stated otherwise.
Transient and stable transfection
Transient transfection of COS-1 and PAE cells was conducted by employing Lipofectamine™/Plus reagents (Invitrogen) according to the manufacturer's instructions. The mutants of c-Kit in pcDNA3 used in the present paper as well as PAE cells stably expressing wild-type and mutant human c-Kit have previously been described [16,21,22]. In all experiments, the GNNK+ (the alternative splice form of human c-Kit containing the peptide sequence GNNK in the extracellular juxtamembrane region) isoform of c-Kit was used [23,24].
Immunoprecipitation, pulldown and Western blotting
Experimental procedures were conducted as described in . Immunodetection was performed by enhanced chemiluminescence using the Super Signal Dura from Pierce (Rockford, IL, U.S.A.) and a CCD camera (charge-coupled-device camera; LAS-3000; Fujifilm).
Affinity fishing of GST fusion proteins with immobilized peptides
The following peptides were synthesized: CEEINGNNY(p)-VYIDPTQ [pY568 (phospho-Tyr568)], CEEINGNNY(p)AYIDPTQ (pY568, Ala569), CEEINGNYY(p)VAIDPTQ (pY568, Ala570), CEEINGNYY(p)VYADPTQ (pY568, Ala571), STNHIY-(p)SNLANCS (pY936), STNHIY(p)ANLANCS (pY936, Ala937), STNHIY(p)SALANCS (pY936, Ala938), STNHIY(p)SNAANCS (pY936, Ala939) and CSDSTNEY(p)MDMKPGV (pY721). Peptides were dissolved at 1 mg/ml in 50 mM Tris buffer (50 mM Tris/HCl, pH 7.4) and 5 mM EDTA (pH 8) and immobilized on Affigel 10 beads (Bio-Rad, Hercules, CA, U.S.A.; 1 mg of peptide/ml of Affigel) according to the manufacturer's instructions. A 1:1 slurry (50 μl) was incubated for 3 h at 4 °C with 1 μg of purified GST–Cbl fusion protein and rolled end-over-end for 3 h in the cold with cell lysates. After thorough washing of the beads, bound protein was eluted by boiling SDS sample buffer, run out on an SDS/10% polyacrylamide gel, electrotransferred to Immobilon-P and probed for GST. For competition experiments, the respective soluble peptide (100 μM) was added to the incubation mixture of fusion protein and immobilized peptides.
In vitro kinase assay
Kinase activity of c-Src was assessed essentially as described in .
Internalization and degradation experiments
Internalization and degradation experiments using 125I-SCF were performed as previously described .
Internalization of c-Kit was determined after stimulation with SCF (100 ng/ml) for the indicated periods of time, using a PE-anti-human CD117 antibody (BD Biosciences Pharmingen) and analysis by flow cytometry using a FACSort instrument (BD Biosciences).
The N-terminal domain of Cbl interacts with c-Kit in a phospho-dependent manner
Several reports indicate that Cbl and tyrosine kinase receptors can interact both directly and indirectly through adaptor proteins such as Grb2, APS or the p85 subunit of PI3K [17,26–28]. To address the issue of whether the interaction between Cbl and c-Kit occurs in a direct or indirect manner, COS-1 cells were transfected with c-Kit and stimulated with 100 ng/ml SCF for 5 min. Lysates were incubated with immobilized GST fusion proteins of either the N-terminal or the C-terminal half of Cbl respectively. Pulled down proteins were separated on an SDS/8% polyacrylamide gel, followed by electrotransfer to Immobilon-P. The filter was first probed with a phosphotyrosine antibody (PY-99), followed by stripping and reprobing with Kit-C1 antibody. A phosphorylation-dependent interaction between the N-terminal region of Cbl and c-Kit could be detected, whereas the C-terminal region of Cbl did not interact with c-Kit (Figure 1A). Efficient transfection and activation of c-Kit in COS-1 cells were confirmed by a parallel immunoprecipitation of c-Kit from the same lysates and probing sequentially for phosphotyrosine and c-Kit.
Interaction of the N-terminal half of Cbl with c-Kit at position Tyr568 and Tyr936
It has previously been suggested that the adaptor protein APS mediates an indirect interaction between Cbl and c-Kit . In order to rule out the contribution of APS to the observed interaction between c-Kit and the N-terminal part of Cbl, we co-transfected COS-1 cells with Myc-tagged APS and c-Kit and performed an analogous pulldown experiment with GST–Cbl (N-term) as described above. Surprisingly, we did not detect an expected enhancement of Cbl–c-Kit interaction by co-transfection of APS (Figure 1B) despite substantial amounts of exogenously expressed APS, while the interaction between Cbl and c-Kit appeared equally strong regardless of the presence or absence of APS. The interaction between APS and Cbl is to some extent SCF-independent, which can be explained by the overexpression of APS in this case. Similar experiments were performed using SH2B and Lnk (lymphocyte-specific adapter protein), members of the same family of adaptor proteins as APS, where no binding of Cbl could be detected (results not shown). We observed that mutation of Ile571 and Leu939 in c-Kit (previously reported to be specific binding determinants for binding of APS to Tyr568 and Tyr936 respectively ) abolished the observed interaction of c-Kit and Cbl-N. This finding suggests that Cbl interacts directly with c-Kit with the same binding determinants as APS (Figure 1C). To verify this interaction in vivo with endogenous levels of Cbl, we performed co-immunoprecipitation between Cbl and c-Kit using cells transfected with either wild-type c-Kit or the I571A/L939A mutant (Figure 1D).
The interaction between Cbl and c-Kit is direct and specifically determined by the +3 positions to Tyr568 and Tyr936
To prove that neither any other molecule besides APS nor endogenous APS is mediating the interaction between Cbl and c-Kit at positions Tyr568 and Tyr936 of c-Kit, we incubated purified GST–Cbl (N-term) fusion protein with immobilized phosphopeptides containing pY568 and pY936. As positive controls for interaction with pY568 or pY936, GST fusion proteins with the SH2 domain of Src or Grb2 were employed respectively (results not shown). Bound proteins were eluted and immunoblotted for GST, revealing that GST–Cbl (N-term) interacts with Tyr568 and Tyr936 in a phosphotyrosine-dependent manner (Figure 2A). Furthermore, the observed interaction could be competed by an excess of soluble phosphopeptide. The competing effect was abolished when peptides with I571A or L939A mutations were used, further supporting the importance of isoleucine/leucine in position +3 to the tyrosine as an important determinant for binding of Cbl to c-Kit (Figure 2B). As a negative control for interaction with Cbl, a peptide based on the peptide sequence around pY721 in c-Kit was used.
Cbl binds directly to phosphorylated Tyr568 and Tyr936 and the specificity is determined by the amino acids at the +3 positions to the tyrosine residues respectively
Our results provide evidence that the N-terminal part of Cbl interacts with c-Kit at position pY568 and pY936 in a direct manner. As we furthermore determined Ile571 and Leu939 as specific determinants for this interaction, we chose the I571/L939A mutant of c-Kit as a specific Cbl loss-of-binding mutant of c-Kit for further phenotypic investigations.
The c-Kit double mutant I571A/L939A possesses intact intrinsic kinase activity and is able to activate Src upon ligand stimulation
In order to exclude the possibility that the I571A/L939A double mutant of c-Kit blocks Cbl interaction because of its potential loss of intrinsic kinase activity, we examined ligand-stimulated autophosphorylation of the receptor. COS-1 cells transfected with either wild-type c-Kit or double mutant c-Kit I571A/L939A were stimulated with SCF and lysates were immunoprecipitated with a c-Kit antibody, Kit-C1. The samples were analysed by Western blotting, probing with a phosphotyrosine antibody (4G10) and reprobed with Kit-C1 for confirmation of equal amount of protein. The kinase activity of the mutant receptor proved to be intact (Figure 3A). Phosphorylated Tyr568 and Tyr936 of c-Kit are known to bind c-Src and Grb2 respectively and both Src and Grb2 have been reported to be involved in Cbl-mediated regulation of RTK signalling via either phosphorylation of Cbl  or indirect recruitment of Cbl to the receptors  respectively. Thus, to exclude that the observed Cbl phenotype of the I571A/L939A double mutant might be a consequence of impaired Src activation, we performed an in vitro Src kinase assay. For this purpose, Src was immunoprecipitated from lysates of cells expressing wild-type c-Kit, the I571/L939A mutant of c-Kit or the Y568F/Y570F mutant, known to be deficient in Src activation , and therefore serving as a negative control respectively. Immunocomplexes were incubated for 15 min at room temperature with [γ-32P]ATP and acid-denatured enolase as an exogenous substrate for Src. Reactions were terminated after 15 min, proteins were separated on an SDS/polyacrylamide gel and electroblotted on to PVDF membranes. Phosphorylated enolase was detected using PhosphoImager (LAS3000; Fujfilm, Tokyo, Japan) and densitometrically analysed. The membranes were reprobed with an Src antibody to ensure equal levels of Src (results not shown). In parallel, the same samples were analysed using Western blotting and probed for anti-phosphotyrosine as well as c-Kit to verify equal amount of expressed protein and activation (results not shown). We could demonstrate that the wild-type c-Kit and the I571A/L939A double mutant show an increased Src kinase activity upon ligand stimulation, whereas the Y568F/Y570F mutant displayed an Src-negative phenotype as expected (Figure 3B). Intact interaction of Grb2 with the I571A/L939A double mutant of c-Kit has previously been demonstrated by Wollberg et al. .
Intrinsic kinase activity and ability to phosphorylate Src of the c-Kit double mutant I571A/L939A
These results demonstrate that the I571A/L939A double mutant of c-Kit is impaired in its ligand-induced binding of Cbl to the c-Kit receptor without abolishing kinase activities of either c-Kit or Src respectively, nor does it inhibit binding of Grb2 to c-Kit.
Phosphorylation and recruitment of Cbl to c-Kit are separable events that both are necessary for receptor ubiquitination
So far we have shown that the I571A/L939A mutant of c-Kit is unable to bind Cbl, but is still capable of activating Src. Next, we were interested to see whether Cbl needs to be recruited to c-Kit in order to be phosphorylated and activated by SFKs. To address this question, COS-1 cells were transfected with wild-type c-Kit as well as the double mutants Y568F/Y570F and I571A/L939A respectively, stimulated with SCF and lysed. Cbl was immunoprecipitated from the lysates and subjected to immunoblotting with anti-phosphotyrosine antibodies. Equal Cbl protein levels were confirmed by reprobing the membrane with an anti-Cbl antibody. Hereby we were able to reveal that phosphorylation of Cbl is deficient in the Y568F/Y570F mutant, but unaffected in the Cbl-I571A/L939A mutant, further confirming that Src kinase activity is intact downstream of I571A/L939A c-Kit (Figure 4). From this, we conclude that Src-dependent phosphorylation of Cbl occurs independently from Cbl interaction with c-Kit and that both events can be temporally and spatially separated. Next, we aimed to examine the ubiquitination phenotype of I571A/L939A c-Kit. The question whether the receptor gets polyubiquitinated or monoubiquitinated following ligand stimulation has not been completely resolved yet in the case of c-Kit. It has been claimed that c-Kit is polyubiquitinated following ligand stimulation and degraded in the proteasomes [15,31], whereas others state that RTKs in general become monoubiquitinated through the action of Cbl, which targets them for degradation in the lysosomes [32,33]. To escape the problem of using an antibody potentially raised against an inappropriate antigen, we chose an anti-ubiquitin antibody recognizing both mono- and poly-ubiquitin moieties (P4D1) for a first experiment. For this, c-Kit was immunoprecipitated from PAE cells that were transiently transfected with the wild-type form, the I571/L939A Cbl-binding mutant or the Y568F/Y570F Src-binding mutant of c-Kit. Immunocomplexes were run on a gel, electrotransferred and probed for ubiquitin. Upon ligand stimulation for 10 min, wild-type c-Kit was markedly ubiquitinated, while none of the c-Kit double mutants displayed receptor ubiquitination despite comparable expression and activation levels of each receptor isoform (Figure 5A). This finding is in accordance with our hypothesis that ubiquitination of c-Kit requires both activation of Cbl by Src and recruitment of phosphorylated Cbl to c-Kit. Thus binding of Cbl to I571/L939 in c-Kit appears to be a specific occurrence secondary to its phosphorylation.
The effect of the wild-type c-Kit versus the two c-Kit double mutants Y568F/Y570F and I571A/L939A on Cbl phosphorylation
Monoubiquitination of c-Kit upon phosphorylation of Tyr568 and Tyr936 and recruitment of Cbl
c-Kit is selectively monoubiquitinated by Cbl
To address the issue of mono- versus poly-ubiquitination of c-Kit, a similar experiment to Figure 5(A) was conducted. This time, membranes containing immunoprecipitated c-Kit proteins were first probed with an antibody specifically reacting with polyubiquitin moieties (FK1), stripped and reprobed with the anti-mono/poly-ubiquitin antibody. As a positive control for a known polyubiquitinated protein, we included immunoprecipitated activated Src . It was consistently observed that only wild-type c-Kit with intact Cbl and Src binding displayed ubiquitination. Furthermore, the ubiquitination signal on c-Kit only became apparent when employing the antibody generated against both mono- and poly-ubiquitin, whereas the specific polyubiquitin antibody did not react with wild-type c-Kit (Figure 5B). Thus it appears that c-Kit is primarily monoubiquitinated upon ligand stimulation in a process that requires Src-dependent phosphorylation and receptor association of Cbl.
Internalization and degradation of c-Kit are dependent on activation of Src and intact Cbl-binding sites
Since it has been demonstrated that ligand-induced monoubiquitination regulates internalization and degradation of several RTKs, we wanted to investigate the effect of inhibition of monoubiquitination on c-Kit internalization and degradation. PAE cells expressing either Y568F/Y570F or I571/L939A mutant forms of c-Kit, which we have shown to inhibit Src-dependent phosphorylation of Cbl or Cbl association respectively, displayed impaired ligand internalization and degradation when compared with wild-type c-Kit (Figure 6A). In addition, inhibition of Src kinase activity by 2 μM SU6656 interfered with degradation of wild-type receptor, which is in agreement with previous reports . We also analysed receptor internalization in Ba/F3 cells expressing wild-type, Y568F/570F or I571A/L939A mutant c-Kit by flow cytometry using an antibody against the extracellular part of c-Kit. Ba/F3 cells were used since they grow in suspension culture and thus do not need to be treated with trypsin in order to do the flow cytometry analysis, which could potentially interfere with receptor detection. In both the Y568F/Y570F and the I571A/L939A mutant c-Kit, internalization of the receptor was decreased compared with wild-type receptor-expressing cells (Figure 6B).
Analysis of degradation of internalized SCF in cells expressing wild-type c-Kit versus I571A/L939A mutant c-Kit and their intracellular processing
Internalized c-Kit is degraded via the lysosomal pathway
It has recently been shown that the EGF receptor is sorted to lysosomes upon EGF stimulation in a Cbl-dependent manner . Moreover, lysosomal degradation has been suggested to be the general degradation pathway following monoubiquitination of proteins (reviewed in ). To test whether c-Kit is degraded in the lysosomes, we examined receptor degradation indirectly by assessing degradation of bound 125I-labelled ligand in the presence or absence of the specific proteasomal or lysosomal inhibitors, lactacystin or chloroquine respectively. Measurement of ligand degradation showed that inhibition of lysosomal action by 20 μM chloroquine completely abolished receptor degradation, whereas inhibition of the proteasome by 100 μM lactacystin only retarded receptor degradation slightly (Figure 6C). Therefore we propose that degradation of c-Kit mainly occurs via monoubiquitination and subsequent targeting to the lysosomes.
The TKB domain of Cbl mediates binding to target proteins containing phosphorylated tyrosine residues and is indispensable for Cbl to induce ubiquitination of target RTKs . Cbl can associate with the activated RTK either directly or through adaptor proteins. The adaptor protein Grb2 is able to associate with Cbl through proline-rich regions in Cbl interacting with the SH3 domain of Grb2 . It was recently suggested that direct versus indirect association of Cbl with the EGF receptor has distinct function . This further suggests that the sites of ubiquitination might differ depending on a direct or indirect interaction with Cbl, which in turn might differentially regulate association with downstream signal transduction molecules. Here, we present evidence that Cbl can interact with c-Kit in a direct manner at position Tyr568 and Tyr936, and that this interaction is dependent on a leucine or isoleucine residue in position +3. Since Tyr568 of c-Kit is the binding site for several signal transduction molecules besides Cbl, including SFKs, SHP-2 (SH2-domain-containing protein tyrosine phosphatase 2) and the adaptor protein APS, we made the I571A mutant of c-Kit to specifically knock out binding of Cbl without affecting Src kinase activity. This also enabled us to study the role of Src kinase activity versus Cbl association with Tyr568 for the activation of Cbl following c-Kit activation. Hereby we could reveal that Cbl phosphorylation by Src and Cbl recruitment to c-Kit are separate events that are both pivotal for Cbl-mediated ubiquitination of c-Kit. This also includes a sequential binding of Src and Cbl to pY568 of c-Kit (see Figure 7).
Proposed model for the sequential Src- and Cbl-dependent steps during the ubiquitination of c-Kit
A number of tyrosine kinases and RTKs have been shown to bind to Cbl through the TKB of Cbl, including the EGF receptor , VEGF receptor [Flt-1 (Fms-like tyrosine kinase-1)] , macrophage CSF-1 receptor , Met receptor , the p75 neurotrophin receptor , the PDGF α-receptor , Zap-70 (zeta-chain associated protein 70) , Syk , Src  and Fyn . Studies on the consensus sequence for binding of the Cbl TKB using degenerate peptide libraries suggested a consensus of NXpY(S/T)XXP . Many Cbl-binding proteins fulfil this consensus sequence requirements, but there are exceptions (Table 1).
|Cbl-binding site sequence||Protein|
|Cbl-binding site sequence||Protein|
|Cbl-binding site sequence||Protein|
|Cbl-binding site sequence||Protein|
The Met receptor has been described to associate with Cbl via an atypical sequence motif . In that case, the required sequence was found to be DpYR. Also the amino acid sequence surrounding Tyr568 and Tyr936 in c-Kit does not strictly meet the requirements of the ‘traditional’ consensus sequence for binding of Cbl to phosphotyrosine residues. Tyr936 has a serine residue in position +1, but otherwise it shows little similarity to the typical Cbl association sites. The two Cbl recruitment sites in c-Kit both have isoleucine/leucine residues in position +3. This is also present in the Cbl association site of the p75 neurotrophin receptor. However, there are no striking similarities. This might point to requirements for Cbl binding that are rather determined by specific tertiary structures than by primary amino acid sequences. One should also keep in mind that the results presented on the binding specificity of Cbl to c-Kit arise from the use of synthetic phosphopeptides derived from the c-Kit sequence and might not fully represent the role of c-Kit in a physiological context.
Ubiquitination of protein has for long time been thought exclusively to occur through polyubiquitination and to target proteins for degradation in the proteasomes. However, in the case of RTKs, it was recently shown that at least some of them undergo multiple monoubiquitination, which targets them for endocytosis and degradation in the lysosomes [32,33]. Several studies have suggested that c-Kit is polyubiquitinated upon ligand stimulation [15,31], but the methods to detect ubiquitination in those studies were not able to distinguish between polyubiquitination and monoubiquitination. In the present study, we have used two types of ubiquitin antibodies: one that is able to recognize both monoubiquitin as well as polyubiquitin (P4D1), and one recognizing only polyubiquitin (FK1). Thus we could show that ubiquitination of c-Kit following ligand stimulation occurs exclusively as monoubiquitination.
Other studies have presented evidence that mono- and poly-ubiquitinations serve distinct purposes. In the case of the receptors for PDGF and EGF, several studies have linked monoubiquitination to regulation of receptor internalization and endosomal routing of receptors for lysosomal degradation [32,33]. By the use of a proteasomal inhibitor, lactacystin, and a lysosomal inhibitor, chloroquine, we showed that degradation of c-Kit is to a large extent dependent on the lysosomal pathway and only to a minor extent on the proteasomal pathway. It has been shown that proteasome inhibitors block lysosomal degradation of ligand, which remains bound to their receptors within the endocytic pathway .
Monoubiquitination and degradation of RTKs through the lysosomal pathways are important pathways for regulating receptor activity. It is striking that in many cases transforming mutants of RTKs and other tyrosine kinases carry mutations that render them unable to bind to the Cbl family of ubiquitin E3 ligases (reviewed in ). Thus escape of lysosomal degradation will allow the receptor to signal for a prolonged period of time and contribute to the transformed phenotype.
In the present paper, we describe a direct interaction between Cbl and c-Kit. Based on our results, we propose a model in which Cbl is activated through Src-mediated phosphorylation and then associates with the receptor. The physical association of Cbl with c-Kit is necessary for c-Kit to become ubiquitinated (Figure 7). The monoubiquitinated receptor is then internalized, sorted to the lysosomes and degraded. In other systems, such as the EGF receptor, direct association versus indirect association via Grb2 has been shown to have distinct functions . One obvious possibility is that direct versus indirect association with Cbl leads to ubiquitination at distinct lysine residues with distinct functional consequences. Future studies aiming at identifying the sites of ubiquitination in wild-type c-Kit, versus the I571A/L939A mutant c-Kit (that is deficient in direct association), versus the Y703F/Y936F mutant that is defective in Grb2 association , will shed light on these issues.
This work was supported by grants from the Swedish Research Council, the Swedish Cancer Society, the research funds at Malmö University Hospital, Alfred Österlund Foundation, Gunnar Nilsson Cancer Foundation and the National Institutes of Health (Bethesda, MD, U.S.A.; to H.B.). E.H. was supported by a postdoctoral fellowship from the Wenner-Gren Foundation and the salary of L.R. is partially funded by the Swedish Research Council.
adapter protein with a pleckstrin homology and Src homology domain
epidermal growth factor
foetal bovine serum
growth-factor-receptor-bound protein 2
cells, porcine aortic endothelial cells
platelet-derived growth factor
really interesting new gene
receptor tyrosine kinase
stem cell factor
Src family kinase
domain, Src homology 2 domain
domain, tyrosine kinase binding domain
vascular endothelial growth factor
Present address: Department of Pharmacognosy, Faculty of Life Sciences, University of Vienna, Althanstrasse 14, A-1090 Vienna, Austria.